Local drug companies find it hard to produce Sputnik's second component

​​A top executive of a drug maker, which has signed a pact with RDIF to manufacture and supply up to 200 million doses of Sputnik V, told ET that with the existing technology, it is not viable to manufacture the second dose at scale.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3AW6tl7
via IFTTT